

4TH ANNUAL DIABETES CTU Clinical · Trials · Update

Saturday, January 12, 2019 | DoubleTree by Hilton, 300 King St. London, ON

FACULTY



Lawrence A. Leiter,
MD, FRCPC, FACP, FACE, FAHA, FACC
CO-CHAIR
Endocrinologist, St. Michael's Hospital
Professor of Medicine and Nutritional Sciences,
University of Toronto,
Toronto, ON



Stewart B. Harris,
CM, MD, MPH, FCFP, FACPM
CO-CHAIR
Professor of Medicine, Family Medicine, and
Epidemiology and Biostatistics;
CDA Chair in Diabetes Management;
Ian McWhinney Chair of Family Medicine Studies,
Western University,
London, ON



John B. Buse,
MD, PhD
Verne S. Caviness Distinguished Professor of Medicine
Chief, Division of Endocrinology
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
Executive Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, NC, USA



Diane J. Donat,
MSc, MEd, MD, FRCPC
University of Toronto
Toronto, ON



Philip A. McFarlane,
MD, PhD, FRCPC
Medical Director, Home Dialysis
Division of Nephrology,
St. Michael's Hospital
Assistant Professor of Medicine,
University of Toronto
Toronto, ON



Subodh Verma,
MD, PhD, FRCSC, FAHA
Cardiac Surgeon, St. Michael's Hospital
Professor of Surgery and Pharmacology
& Toxicology, University of Toronto,
Canada Research Chair in Cardiovascular Surgery
Toronto, ON

AGENDA

7:30 am	Registration and Breakfast	
8:10 am	Welcome and Opening Remarks	Lawrence A. Leiter
Session 1		
8:20 am	DPP-4 inhibition: New data and clinical implications	Diane J. Donat
8:40 am	SGLT2 inhibition: What have we learned from clinical trials?	Lawrence A. Leiter
9:00 am	Choosing between DPP-4 inhibitors and SGLT2 inhibitors as add-on therapies to metformin	Stewart B. Harris
9:20 am	Panel discussion	
9:50 am	Refreshment Break	
Session 2		
10:20 am	Renal protection in diabetes: New and upcoming data with SGLT2 inhibitors and ARN inhibitors	Philip A. McFarlane
10:40 am	Primary prevention of heart failure in diabetes: Why is it important and how can it be accomplished?	Subodh Verma
11:00 am	PCSK9 inhibition in diabetes: What have we learned from the sub-analyses of larger trials?	Lawrence A. Leiter
11:20 am	Panel discussion	
Session 3		
11:50 am	GLP-1 receptor agonists and cardiometabolic protection: What are the latest data?	Subodh Verma
12:10 pm	New glucose lowering therapies in patients with diabetes and weight loss: A New Era	Stewart B. Harris
12:30 pm	Panel discussion	
1:00 pm	Lunch	
Session 4		
1:50 pm	High risk secondary prevention: Lessons from CANTOS, COMPASS and PARAGON-HF	Subodh Verma
2:10 pm	Insulin therapies in diabetes: New data and updated guidelines	Diane J. Donat
Keynote Presentation		
2:30 pm	Real world evidence and what they could tell us	John B. Buse
3:00 pm	Panel discussion	
3:30 pm	Closing Remarks	

There is no registration fee to attend. Meals and meeting materials provided.

For more information about this program please contact
S&L Solutions at **289-232-4229** or info@slsolutionsevents.ca

TO REGISTER: www.DiabetesCTULondon2019.com

This program has received an educational grant from: AstraZeneca, Bayer, Boehringer-Ingelheim Eli Lilly, Janssen, Merck, Novartis, Sanofi